About Parkinson’s Disease2018-02-02T04:07:39+00:00

Parkinson’s disease affects between 1 and 1.5 million Americans, with between 40,000 and 60,000 new cases diagnosed each year. The mean age of diagnosis is 62, although 5 to 10% of individuals with Parkinson’s disease have young-onset Parkinson’s, which manifests before the age of 45. Individuals may be diagnosed in the earlier or later stages of the disease, and symptoms may progress more rapidly in some people than others. However, there is a common pattern to the course of Parkinson’s disease, linked to the progressive loss of dopaminergic nerve cells in the brain and body.

Dopamine is a neurotransmitter, or a chemical that transmits messages between nerve cells. Parkinson’s disease is associated with the death of neurons (nerve cells) that produce dopamine, leading to decreased levels of dopamine in the brain and body. The death of these cells causes malfunctioning of pathways that rely on dopamine to carry messages, including the neural pathways controlling movement. Some loss of dopamine cells in the brain is expected with normal aging, but with Parkinson’s disease the loss is accelerated and more pronounced.

The symptoms of Parkinson’s are related to dopamine cell loss.

The timeline of Parkinson’s disease follows the pattern of loss in dopamine nerve cells. This progression in cell damage was translated into six stages of the disease by a researcher named Dr. Heiko Braak. In the Braak staging system, Stage 1 of Parkinson’s is a pre-symptomatic stage; at this point in the disease, cell loss is occurring but is not yet significant enough to cause any symptoms. In late Stage 1 and Stage 2, the first premotor symptoms appear. Loss of dopamine nerve cells in the olfactory bulb results in a diminished sense of smell, or hyposmia. Neuronal loss in the enteric plexus (nerve supply of the intestine) results in constipation. Loss of neurons in the sleep centers of the brain, including the reticular formation, may result in sleep disorders, including REM sleep behavior disorder.

Onset of the classic motor symptoms of Parkinson’s disease.

It is only in Stage 3 that the classic motor symptoms of Parkinson’s disease, including tremor and dyskinesias, begin to appear. This may be many years after the onset of the disease, as measured by loss of dopamine nerve cells. Motor symptoms are related to the loss of dopamine-containing neurons in a specific part of the brain called the substantia nigra. It is estimated that 50% or more of the cells must be lost before the motor symptoms begin to manifest. The loss of these dopaminergic neurons disrupts the function of the striatum, a part of the brain controlling movement. By Stage 4, cell loss has spread to the mesocortex.

Advanced Parkinson’s Disease

In Braak Stage 5 and 6, cell loss involves the higher cortical centers of the brain, which control functions such as cognition and emotion. The progressive loss of these neurons may lead to confusion and dementia. Approximately 50% of individuals with Parkinson’s disease suffer from frank dementia by the time they have reached 20 years living with the disease. Other neuropsychiatric disorders can include depression, anxiety, apathy and hallucinations. Sleep disorders, including insomnia and daytime sleepiness, are also common. While the progression of Parkinson’s disease typically follows this pattern, starting outside of the brain and in the brainstem (base of the brain) and progressing to higher centers of the brain including the cerebral cortex, the speed at which that progression occurs and the specific symptoms associated with the dopamine cell loss can vary greatly between individuals. The Colorado Neurological Institute specializes in creating personalized treatment plans for individuals suffering from Parkinson’s disease.

Reduction of Levodopa Therapy for Dyskinesia

With ongoing Levodopa therapy for months or more commonly, a few years of treatment, two major types of motor complications tend to arise: motor fluctuations and dyskinesias. Motor fluctuations are variations in mobility associated with the effectiveness of levodopa when patients can tell when their medications kick in and wear off (the short duration response to levodopa). As the [...]

By |May 13th, 2022|Categories: Dyskinesia|0 Comments

Amantadine Products

Amantadine is also an older medication which was initially developed to help prevent influenza Type A. It was subsequently found to have a mild but definite effect on Parkinson’s without worsening typical symptoms. More recently, it has been found to be helpful in reducing levodopa-induced dyskinesias and now is predominantly used in advanced Parkinson’s disease for this purpose. Furthermore, [...]

By |May 13th, 2022|Categories: Dyskinesia|0 Comments

Invasive Therapies

Fortunately, there are more advanced options to consider if medical therapies do not seem to alleviate the symptoms of dyskinesia: Deep Brain Stimulation (DBS) Deep brain stimulation (DBS) should be considered for patients who have disabling motor fluctuations and dyskinesias despite optimal medication therapy or severe medication-refractory tremor.  Surgery should not be unnecessarily delayed when patients cannot practically be [...]

By |May 12th, 2022|Categories: Dyskinesia|0 Comments

Recognizing and Treating Dyskinesia

Both dyskinesia and “off” episodes are common later in the disease course of Parkinson’s. Sometimes patients and their caregivers often have difficulty differentiating between the two states. This article aims to help clarify this differences and discuss available treatment options. Dyskinesia Dyskinesia is an involuntary muscle movement and irregular [...]

By |April 5th, 2022|Categories: About Parkinson's Disease, De Novo|1 Comment

Member Testimonials

See why our members rate Parkinson's Community 4.9/5 ⭐ "That's what your whole purpose is, to help those that have Parkinson's and to give us more information and answer our questions" "It's exactly what we need, people with Parkinson's need all the help we can get" "It makes a difference to know there are people [...]

By |March 18th, 2022|Categories: Uncategorized|0 Comments

Inadequately Controlled Motor Fluctuations

Options Overview for Inadequately Controlled Motor Fluctuations As Parkinson’s disease progresses, the response to levodopa becomes more complex and medication beneficial effects begin to wear off between doses.   The variations in mobility such that patients can tell when their medications kick in and wear off are referred to as motor fluctuations.  Although motor fluctuations can be very frustrating and [...]

Go to Top